2008
DOI: 10.1097/00042728-200802000-00002
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of Lentigo Maligna with Imiquimod before Staged Excision

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
88
0
1

Year Published

2009
2009
2018
2018

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 85 publications
(91 citation statements)
references
References 20 publications
2
88
0
1
Order By: Relevance
“…11 However, imiquimod remains an off-label indication for melanoma because of the lack of randomized, prospective trials demonstrating its efficacy compared with conventional surgery. 7,13,[17][18][19][20] A thorough discussion of risks and benefits is necessary so that patients/families understand the limitations of treatment with imiquimod over standard surgical resection, including the risk of missing or undertreating invasive melanoma, local recurrence caused by lack of histologic margin control, and absence of long-term randomized controlled trials or comparative studies. 11 Close follow-up is recommended in patients treated with imiquimod, along with a low threshold to perform ''scouting'' biopsies after treatment and biopsy of any recurrent pigmentation in imiquimod-treated sites.…”
Section: Discussionmentioning
confidence: 99%
“…11 However, imiquimod remains an off-label indication for melanoma because of the lack of randomized, prospective trials demonstrating its efficacy compared with conventional surgery. 7,13,[17][18][19][20] A thorough discussion of risks and benefits is necessary so that patients/families understand the limitations of treatment with imiquimod over standard surgical resection, including the risk of missing or undertreating invasive melanoma, local recurrence caused by lack of histologic margin control, and absence of long-term randomized controlled trials or comparative studies. 11 Close follow-up is recommended in patients treated with imiquimod, along with a low threshold to perform ''scouting'' biopsies after treatment and biopsy of any recurrent pigmentation in imiquimod-treated sites.…”
Section: Discussionmentioning
confidence: 99%
“…17,20 An efficacy rate of 50% based on 10 patients followed up for a mean of 33 months (range, 11-56 months) has been recently reported. 21 Two previous studies 2,4 based on histopathologic assessment of the complete surgical excision specimen reported histopathologic clearance rates of 67% (4 of 6) and 75% (30 of 40) ( Table 2). Their efficacy rates and our rate of 53% (20 of 38) are noted to be lower than those of other studies, 1,3,[5][6][7][8][9][10][11][12][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41] which used partial biopsy findings or macroscopic clearance to assess efficacy.…”
Section: Commentmentioning
confidence: 97%
“…59,74-76 In 1 study of 40 patients, use of imiquimod 5 times a week for 3 months before staged excision resulted in no recurrences at 18 months. 75 Patients who use imiquimod plus tazarotene may have even better responses compared to the use of imiquimod alone. 59 However, there is a lack of randomized controlled trials examining the use of imiquimod with or without tazarotene before surgery compared with surgery alone.…”
Section: Staged Excision Key Pointsmentioning
confidence: 99%